Make Informed Investment Decisions with Affordable Access to Experts
Edison will be hosting a call to discuss new CNS drugs including esketamine, SAGE-547, and SAGE-217.Ticker(s): SAGE, AGN, JNJ
Name: Dr Michael Thase - MD
Institution: Private Practice & UPenn
- Professor of Psychiatry at the Perelman School of Medicine of the University of Pennsylvania.
- Leading figure in the pharmacotherapy of mood disorders. Research focuses on the assessment and treatment of mood disorders, including studies of the differential therapeutics of both depression and bipolar affective disorder.
- Has authored or co-authored more than 500 scientific articles and book chapters, as well as 15 books.
This expert call is sponsored by Edison, a global advisory and independent research company. Edison's world renowned equity research platform provides deep multi-sector knowledge and an extensive network of investors, advisors and companies providing clients with a differentiated approach to advisory services. This enables Edison to truly understand its clients’ businesses and their needs and to engage more fully with stakeholders on their behalf and in a more targeted way.
CALL LEADER: Maxim Jacobs, Director of Healthcare Research, North America
Maxim joined Edison in 2015 from Guidepoint Global, where he was a Director of Survey and Tracker Research, conducting extensive primary research across healthcare markets. He also brings more than 15 years’ experience in equities to the healthcare team previously holding positions at Ridgemark Capital, Broadfin Capital, and Mehta Partners.
Please describe your background and clinical practice. How do you currently treat patients with MDD and PPD?Added By: joe_mccann
What is the potential for esketamine in patients with Major Depressive Disorder.Added By: joe_mccann
How many post-partum depression patients would be severe enough to be willing to sit through a 60 hour infusion of SAGE-547?Added By: joe_mccann
Do you think SAGE-217 will have a different profile than classes of drugs with a similar mechanism, such as benzodiazepines.Added By: joe_mccann
What are the chemical or pharmacokinetic differences between SAGE-547 and other synthetic formulations of allopregnanolone (e.g. ganoxolone)? Would these differences be expected to have any clinical impact?Added By: festina_lente
Among the rapid acting antidepressant candidates in late stage clinical trials, can you summarize the clinical data comparing ketamine and derivatives like esketamine to glutamate NR2B modulators such as GLYX-13? Which group might be expected to have greater safety, efficacy, favorable pharmacokinetic properties or clinical utility?Added By: festina_lente
Do you expect that the advantages of SAGE 217 over SAGE 547 and ganoxolone publicized in pre-clinical studies (rodent plasma to brain ratio, potency of GABA modulation, less off target activity) will manifest in any difference in clinical efficacy/safety? In other words, assuming eventual regulatory approval for this class of drugs, in your opinion, how likely are clinicians to choose SAGE 217 over SAGE 547 or ganoxolone (in psychiatric indications)?Added By: festina_lente
Given the linkages between postpartum depression and bipolar disorder, would you expect that the neurosteroid antidepressants would also have efficacy in bipolar depression?Added By: festina_lente
Can you comment on your opinion of the psychomimetic side effect profile of esketamine? It seems mechanistically unlikely that an enantiomer of ketamine would not have at least some of the psychomimetic and dissociative qualities of racemic ketamine. In other antidepressants, enantiomeric formulations have been criticized as being "me-too" drugs, introduced as patent life extenders rather than novel clinical formulations.Added By: festina_lente
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.